UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|----------------------- ...

Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS • Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively • Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 • Co ...

Aurinia Pharmaceuticals (AUPH) shares ended the last trading session 6.6% higher at $5.86. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.9% gain over the past four weeks.The rise in share price was attributable to positive investor expectations for Lupkynis, the company’s sole marketed drug which is approved for treatment of adults with active lupus nephritis (LN). Sales of the drug are being driven predominant ...

Aurinia Pharmaceuticals (AUPH) shares rallied 5.6% in the last trading session to close at $5.65. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks.The sudden soar in the stock price of the company is likely due to the positive momentum built around its pipeline. Aurinia's sole-marketed product, Lupkynis, is approved in the United States for the treatment of lupus nephritis. T ...

Aurinia Pharmaceuticals (AUPH) closed the last trading session at $5.16, gaining 3.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.14 indicates a 96.5% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $3.13. While the lowest estimate of $6 indicates a 16.3% increase from the current price level, the most optimistic anal ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Farzin Haque - Jefferies Stacy Ku - TD Cowen Joseph Schwartz - Leerink Partners Ed Arce - H.C. Wainwright David Martin - Bloom Burton Operator Greetings, and welcome to the Au ...

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 82.35%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.18 per share when it actually produced a loss of $0.19, delivering a surprise of -5.56%.Over the last four quarters, th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|---------------------- ...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current Program. Aurinia announced on February 15th that its Board of Directors (the “Board”) had approved a ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Conference Call February 15, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Farzin Haque - Jefferies Stacy Ku - TD Cowen Ed Arce - HC Wainwright Operator Greetings. Welcome to Aurinia Pharmaceuticals' Full Year 2023 Earnings Call. At this time, all participants are in a listen-onl ...